The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 163:1826-1829, October 2006
doi: 10.1176/appi.ajp.163.10.1826
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Reynolds, G. P.
* Articles by San, L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Reynolds, G. P.
* Articles by San, L.
Related Collections
* Neurotransmitters
* Schizophrenia Spectrum Disorders
* Genetics
*Related Article

Brief Report

Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients

Gavin P. Reynolds, Ph.D., Belen Arranz, M.D., Ph.D., Lucy A. Templeman, Ph.D., Sofia Fertuzinhos, B.S., and Luis San, M.D., Ph.D.

OBJECTIVE: The serotonin 5-HT1A receptor may modulate some of the negative, cognitive, and affective symptoms of schizophrenia and is a potential target of action of some antipsychotic drugs. A functional polymorphism in the promoter region of the 5-HT1A receptor gene is associated with depression and suicidal behavior. The authors sought to determine whether this polymorphism influences symptom response to antipsychotic drug treatment. METHOD: Sixty-three drug-naive patients with first-episode psychosis who were genotyped for the –1019C/G polymorphism were recruited for this study and received standard care. The Positive and Negative Syndrome Scale and the Calgary Depression Scale were used to monitor symptom changes over 3 months. RESULTS: The polymorphism was associated with, and accounted for much of the variance in, changes in negative and depressive symptoms but not positive symptoms. CONCLUSIONS: These findings identify an important genetic factor predicting much of the response in negative and depressive symptoms to antipsychotic drug treatment.


Related Article:

In This Issue
Am J Psychiatry 2006 163: A62. [Full Text] [PDF]






Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org